EGFR and ovarian serous adenocarcinoma: Checkpoint kinase 1 (Chk1) and epidermal growth factor receptor (EGFR) are therapeutic targets for treatment of acute and chronic leukemias [152] and high-grade serous ovarian cancer [153,154].